This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 31 from Patent US 20110319336
General Information
DRACP ID DRACP01396
Peptide Name Sequence 31 from Patent US 20110319336
Sequence WHSDMEWWYLLG
Sequence Length 12
UniProt ID Not available
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification CONH2 is existing at C-terminal
Other Modification None
Chiral L
Physicochemical Information
Formula C79H99N17O19S
Absent amino acids ACFIKNPQRTV
Common amino acids W
Mass 181921
Pl 4.18
Basic residues 1
Acidic residues 2
Hydrophobic residues 5
Net charge -1
Boman Index -361
Hydrophobicity -49.17
Aliphatic Index 65
Half Life
Mammalian: 2.8 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 17990
Absorbance 280nm 1635.45
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2011/0319336 A1
Patent Title Selective anticancer chimeric peptide.
Other Iinformation Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013
Other Published ID CN102238965A EP2370107A2 WO2010064207A2 WO2010064207A3
This work is licensed under a Creative Commons Attribution 4.0 International License.